Shares of Johnson & Johnson JNJ,
Monday, as the company approaches the early release of the provisional results of a final-stage clinical trial evaluating its single-dose COVID-19 vaccine candidate. J&J said in mid-December it expects to share the findings of the phase 3 trial in late January, which would be the third company to test coronavirus vaccines in the United States to announce the results of a trial of phase 3 closely monitored. The other two vaccines, developed by BioNTech SE BNTX,
/ Pfizer Inc. PFE,
and Modern Inc. MRNA,
both are mRNA-based vaccines that received emergency use authorization from the Food and Drug Administration in December. J&J said in December that it will apply for emergency clearance for its adenovirus-based experimental vaccine in February if results are ready by the end of January. The company is expected to post its fourth-quarter and full-year earnings on Tuesday. Shares of J&J have gained 10.9% over the past year, while the S&P 500 SPX,
increases by 15.6%.